Age de-escalation study to assess safety and immunogenicity of recombinant E. coli BK-SE36 malaria vaccine candidate formulated with CpG adjuvant administered intramuscularly in healthy malaria exposed African adults and children living in Burkina Faso.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Malaria vaccine (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors Nobelpharma
- 21 Aug 2017 Planned initiation date changed from 30 Jun 2017 to 30 Sep 2017.
- 07 Feb 2017 New trial record